Navigation Links
Glucosamine Fails Osteoarthritis Test
Date:10/20/2009

Popular supplement doesn't prevent loss of cartilage in knee, study finds

TUESDAY, Oct. 20 (HealthDay News) -- Glucosamine takes a hit in a new study that finds it doesn't prevent cartilage loss in people with osteoarthritis of the knee, University of Pittsburgh researchers report.

Many arthritis sufferers take glucosamine supplements in an attempt to reduce pain or to slow the disease's progression, but previous studies have questioned its effectiveness.

In this new study, Dr. C. Kent Kwoh, professor of medicine and epidemiology in the university's division of rheumatology and clinical immunology, had 201 people with mild to moderate knee pain randomly assigned to receive glucosamine or placebo. The study participants underwent MRI and X-ray screening at the start of the trial and 24 weeks later.

Kwoh's group found the same progression of cartilage damage in those who received glucosamine as in those who received placebo. Worsening bone lesions were also the same for both groups, and there was no difference in cartilage synthesis between the groups, the researchers noted.

The result of the study is "not surprising," said Dr. Carlos Lozada, an associate professor of rheumatology and immunology at the University of Miami Leonard M. Miller School of Medicine, who was familiar with the study.

"The larger studies that have been done to date looking at cartilage preservation using glucosamine have essentially been negative," Lozada said.

These new results were scheduled to be presented Tuesday at the American College of Rheumatology Annual Scientific Meeting, held Oct. 17 to 21 in Philadelphia.

"In this six-month study using state-of-the-art MR imaging, we were not able to demonstrate any benefit of glucosamine on the prevention of worsening joint damage in individuals with mild to moderate knee pain," Kwoh said in a prepared statement.

Osteoarthritis, the most common joint disease among middle-aged and older people, results from progressive damage to the joint cartilage. The disease causes fluid accumulation, bony overgrowth, and loosening and weakness of muscles and tendons, which can limit movement and cause pain and swelling.

Weight-bearing joints -- the knees, hips and spine -- are most often affected. Osteoarthritis in the knee and hip can result in chronic pain or discomfort while standing or walking.

Glucosamine, a natural compound, is part of healthy cartilage. Another recent study found no evidence that glucosamine supplements had any effect on pain or function, and no improvement was noted in the X-rays of people taking it.

Despite these results, Lozada thinks glucosamine might have a role in managing pain. There are studies suggesting that that is possible -- but the studies have been conflicting.

"For most doctors, glucosamine is not a standard recommendation for treating osteoarthritis," Lozada said. "It is something you might mention to a patient who is motivated to try nutritional supplements," he said.

If a patient has tried other painkillers, weight loss and exercise, and these haven't worked, then the doctor might mention trying glucosamine, Lozada said. "But it is in no way something every single patient should try," he said. "We really don't have the data to support that."

More information

For more information on osteoarthritis, visit the U.S. National Library of Medicine.



SOURCES: Carlos Lozada, M.D., associate professor, rheumatology and immunology, University of Miami Leonard M. Miller School of Medicine; Oct. 19, 2009, news release, American College of Rheumatology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
2. Study Suggests Glucosamine Wont Ease Hip Arthritis
3. Pharma Base S.A. Launches Osamine(TM) Pharmaceutical Grade Glucosamine in North America
4. Studies Struggle to Gauge Glucosamines Worth
5. Federal research plan to determine nanotech risks fails to deliver
6. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
7. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
8. Experimental Drug Fails Against Heart Failure
9. NSAID Drug Therapy Fails to Ease Back Pain
10. MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements
11. Steroid Fails to Ease Meningitis in Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its ... for alumni, family, friends, and community. “Coming Home 2017” will be held ...
(Date:1/20/2017)... ... 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for ... mounted on wheels, it can be wheeled out of the way and stored when not ... deck. "We have transformed the feedback from customers into specific enhancements and created a new ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are fully ... - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 lens ... and light leak transitions have a very high-dynamic range for super smooth falloff. Simply ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast ... ... Sales Volume, Company Analysis and Forecast to 2022 provides a ... The growing prevalence of hearing impairment coupled with an ...
(Date:1/20/2017)... -- Stock-Callers.com today evaluates the following Drug Manufacturers ... Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. ... (NASDAQ: PTX ). These stocks belong to the ... 2017, finishing near its session lows. As per a NASDAQ ... shares of health care companies in the S&P 500 also ...
Breaking Medicine Technology: